Payers Create CAR-T Approval Systems As Adoption Increases
Source: Precision ADVANCE
By Jane Anderson
Content featured by Precision Value & Health
Spurred by CMS’s decision to cover CAR-T cell therapies under Medicare, commercial payers are beginning to systematize approvals for CAR-T treatment as use of these breakthrough cancer therapies is beginning to ramp up. In this article experts weigh in on factors driving authorizations now and what to expect as more CAR-T therapies are approved.
access the Article!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.
Subscribe to Cell & Gene
X
Subscribe to Cell & Gene
Precision ADVANCE
This website uses cookies to ensure you get the best experience on our website. Learn more